Highlights Atreca, Inc.

Equities

BCEL

US04965G1094

Delayed OTC Markets Other stock markets 12:02:57 2024-05-08 pm EDT			5-day change	1st Jan Change
0.0905 ^USD	-2.45%		+0.78%	-31.44%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	North American Morning Briefing : Traders Await -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	Dec. 26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	Dec. 25	CI
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract	23-06-05	CI
Atreca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Atreca, Inc. Reports Additional Data from Ongoing Phase 1b Trial	23-03-29	CI
Atreca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-29	CI
Atreca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Atreca, Inc. and Xencor, Inc. to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target	23-02-06	CI
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Atreca to Cut Around 33 Jobs to Conserve Cash, Fund Testing of Prospective Cancer Drugs	22-06-01	MT
Atreca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101	22-05-04	CI
Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology	22-04-05	CI
Atreca Q4 Loss Widens; Releases Solid Tumor Trial Data -- Shares Plunge Friday Afternoon	22-03-04	MT
Atreca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Atreca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-03-03	CI
Atreca, Inc. to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs	22-01-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Atreca, Inc.

Equities

BCEL

US04965G1094

Highlights

Filters